Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim plus predniso(lo)ne versus predniso(lo)ne alone in previously untreated primary immune thrombocytopenia
2026-525454-11-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of romiplostim and prednisolone in immune thrombocytopenia (ITP) (2 arms), sponsored by Amgen. Primary endpoint: Durable platelet response. Planned start Sep 2026; status: authorised.
02
Drugs
romiplostimprednisolone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2026-525454-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525454-11-00.